These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 23866349)

  • 1. Belimumab. No tangible efficacy but a risk of immunosuppression.
    Prescrire Int; 2013 Jun; 22(139):149. PubMed ID: 23866349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
    Ginzler EM; Wallace DJ; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Zhong ZJ; Freimuth WW; Petri MA;
    J Rheumatol; 2014 Feb; 41(2):300-9. PubMed ID: 24187095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.
    Wallace DJ; Navarra S; Petri MA; Gallacher A; Thomas M; Furie R; Levy RA; van Vollenhoven RF; Cooper S; Zhong ZJ; Freimuth W; Cervera R;
    Lupus; 2013 Feb; 22(2):144-54. PubMed ID: 23213069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
    Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
    BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Belimumab: review of use in systemic lupus erythematosus.
    Boyce EG; Fusco BE
    Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Belimumab for systemic lupus erythematosus: a practice-based view.
    Parodis I; Axelsson M; Gunnarsson I
    Lupus; 2013 Apr; 22(4):372-80. PubMed ID: 23553780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus.
    Merrill JT; Ginzler EM; Wallace DJ; McKay JD; Lisse JR; Aranow C; Wellborne FR; Burnette M; Condemi J; Zhong ZJ; Pineda L; Klein J; Freimuth WW;
    Arthritis Rheum; 2012 Oct; 64(10):3364-73. PubMed ID: 22674457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.
    Zhang F; Bae SC; Bass D; Chu M; Egginton S; Gordon D; Roth DA; Zheng J; Tanaka Y
    Ann Rheum Dis; 2018 Mar; 77(3):355-363. PubMed ID: 29295825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N; D'Cruz DP
    Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus.
    Chatham W; Chadha A; Fettiplace J; Kleoudis C; Bass D; Roth D; Gordon D
    Lupus; 2017 Dec; 26(14):1483-1490. PubMed ID: 28467293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Belimumab: targeted therapy for lupus.
    Chugh PK; Kalra BS
    Int J Rheum Dis; 2013 Feb; 16(1):4-13. PubMed ID: 23441766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial.
    Jones A; Muller P; Dore CJ; Ikeji F; Caverly E; Chowdhury K; Isenberg DA; Gordon C; Ehrenstein MR
    BMJ Open; 2019 Dec; 9(12):e032569. PubMed ID: 31848169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
    Stohl W; Schwarting A; Okada M; Scheinberg M; Doria A; Hammer AE; Kleoudis C; Groark J; Bass D; Fox NL; Roth D; Gordon D
    Arthritis Rheumatol; 2017 May; 69(5):1016-1027. PubMed ID: 28118533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial.
    Tanaka Y; Bass D; Chu M; Egginton S; Ji B; Struemper H; Roth D
    Mod Rheumatol; 2019 May; 29(3):452-460. PubMed ID: 29792370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
    Roth DA; Thompson A; Tang Y; Hammer AE; Molta CT; Gordon D
    Lupus; 2016 Apr; 25(4):346-54. PubMed ID: 26385220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.
    Doria A; Bass D; Schwarting A; Hammer A; Gordon D; Scheinberg M; Fox NL; Groark J; Stohl W; Kleoudis C; Roth D
    Lupus; 2018 Aug; 27(9):1489-1498. PubMed ID: 29807477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
    Tanaka Y; Bass D; Chu M; Egginton S; Ji B; Roth D
    Mod Rheumatol; 2020 Mar; 30(2):313-320. PubMed ID: 31199180
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan.
    Muller P; Chowdhury K; Gordon C; Ehrenstein MR; Doré CJ
    Trials; 2020 Jul; 21(1):652. PubMed ID: 32677992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-marketing experiences with belimumab in the treatment of SLE patients.
    Askanase AD; Yazdany J; Molta CT
    Rheum Dis Clin North Am; 2014 Aug; 40(3):507-17, viii. PubMed ID: 25034159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus.
    Schwarting A; Dooley MA; Roth DA; Edwards L; Thompson A; Wilson B
    Lupus; 2016 Dec; 25(14):1587-1596. PubMed ID: 27488472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.